Effect of crystalline and amorphous forms of N-butyl-1,5-dideoxy-1,5-imino-d-glucitol on technological processes in production of the finished dosage form

Abstract

The bioequivalence of finished dosage forms obtained from pharmaceutical compositions containing amorphous and crystalline forms of N-butyl-1,5-dideoxy-1,5-imino-D-glucitol as the active ingredient was demonstrated